Effects of dendritic core-shell glycoarchitectures on primary mesenchymal stem cells and osteoblasts obtained from different human donors by Lautenschläger, Stefan et al.
Lautenschläger et al. J Nanobiotechnol  (2015) 13:65 
DOI 10.1186/s12951-015-0128-y
RESEARCH
Effects of dendritic core–shell 
glycoarchitectures on primary mesenchymal 
stem cells and osteoblasts obtained 
from different human donors
Stefan Lautenschläger1*, Christin Striegler2, Olga Dakischew1, Iris Schütz1, Gabor Szalay3, Reinhard Schnettler1, 
Christian Heiß1,3, Dietmar Appelhans2 and Katrin S. Lips1
Abstract 
The biological impact of novel nano-scaled drug delivery vehicles in highly topical therapies of bone diseases have 
to be investigated in vitro before starting in vivo trials. Highly desired features for these materials are a good cellular 
uptake, large transport capacity for drugs and a good bio-compatibility. Essentially the latter has to be addressed as 
first point on the agenda. We present a study on the biological interaction of maltose-modified poly(ethyleneimine) 
(PEI-Mal) on primary human mesenchymal stem cell, harvested from reaming debris (rdMSC) and osteoblasts 
obtained from four different male donors. PEI-Mal-nanoparticles with two different molecular weights of the PEI core 
(5000 g/mol for PEI-5k-Mal-B and 25,000 g/mol for PEI-25k-Mal-B) have been administered to both cell lines. As well 
dose as incubation-time dependent effects and interactions have been researched for concentrations between 1 μg/
ml to 1 mg/ml and periods of 24 h up to 28 days. Studies conducted by different methods of microscopy as light 
microscopy, fluorescence microscopy, transmission-electron-microscopy and quantitative assays (LDH and DC-pro-
tein) indicate as well a good cellular uptake of the nanoparticles as a particle- and concentration-dependent impact 
on the cellular macro- and micro-structure of the rdMSC samples. In all experiments PEI-5k-Mal-B exhibits a superior 
biocompatibility compared to PEI-25k-Mal-B. At higher concentrations PEI-25k-Mal-B is toxic and induces a directly 
observable mitochondrial damage. The alkaline phosphatase assay (ALP), has been conducted to check on the possi-
ble influence of nanoparticles on the differentiation capabilities of rdMSC to osteoblasts. In addition the production of 
mineralized matrix has been shown by von-Kossa stained samples. No influence of the nanoparticles on the ALP per 
cell has been detected. Additionally, for all experiments, results are strongly influenced by a large donor-to-donor vari-
ability of the four different rdMSC samples. To summarize, while featuring a good cellular uptake, PEI-5k-Mal-B induces 
only minimal adverse effects and features clearly superior biocompatibility compared to the larger PEI-25k-Mal-B.
© 2015 Lautenschläger et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Dendritic polymers feature versatile molecular archi-
tectures with multifunctional properties [1–6]. Tailored 
by the fabrication of the dendritic scaffold, the result-
ing dendritic polymers can provide multifunctional key 
features such as high water-solubility [7], complexing 
properties [8], conjugation properties [9, 10], self-assem-
bling properties [11–13] and various biological proper-
ties [1–16]. In result complex dendritic structures have 
been impressively used in the field of biomedical applica-
tions over the last decade.
In line with this, first trials have been undertaken with 
dendritic polyamine scaffolds based on various (hyper-)
branched poly(ethylene imines) (PEI) to use them as non-
viral vectors for small-interfering-(si)-RNA [8, 17] and 
DNA [17–20]. PEI nanoparticles show on the one hand 
high cellular uptake rates and high transfection efficacies 
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while on the other hand certain negative effects of viral-
vectors like for example immune responses might be 
reduced or even not present. Initial enthusiasm cooled 
down a little bit because of problems that occur with the 
naked, unmodified PEI-nanoparticles. Negative effects 
are reported to be mainly high toxic effects due to posi-
tive charges and intercalation with DNA [18, 21], also the 
generation of reactive oxide species (ROS) is discussed 
[22–24]. Therefore approaches to enhance biocompatibil-
ity and cellular uptake have been undertaken. For exam-
ple polyglutaminic acid-chains [25], oligosaccharide units 
[26, 27] or different other modifications [28, 29] have 
been introduced to better shield the PEI-core from the 
biological environment.
Especially, dendritic glycopolymers based on PEI or 
poly(propylene imine) cores exhibited their medical, 
pharmaceutical and biological potential, for example, as 
drug-delivery-system (DDS) [30–33], polymeric thera-
peutics and diagnostics [18, 21, 34–36], and artificial 
tubulating agents [22, 37]. The different interaction fea-
tures of the dendritic glycopolymers against drug mol-
ecules, peptides, oligo-/polynucleic acids, proteins and 
various cells can be considered as highly adaptable. This 
key pivotal property is preferentially characterized by the 
multivalent interaction properties of the oligosaccharide 
architectures. This key property is further governed by 
the size and shape of the dendritic scaffold and (surface) 
charge of dendritic glycopolymers. Thus, it gives us the 
chance to capture new biomedical research topics with 
these highly adaptable dendritic glycopolymers.
However the careful evaluation of newly designed 
materials is crucial. In vitro trials are the first set of exper-
imental methods available to investigate combinations 
of living cells and newly designed materials. Of course, 
as it is well known from biological systems, that a large 
donor-to-donor variety of cellular response on external 
influences exist. Commercial available cells are mostly 
available from one single donor only and cannot suf-
ficiently account for that variety. Mesenchymal primary 
stem cells, harvested from the reaming debris (rdMSC) 
of different donors [38, 39], are suitable to overcome that 
limitation. In consequence the aim of this study was to 
carefully investigate the influence of the maltose-mod-
ified PEI nanoparticles against different rdMSC, har-
vested from multiple healthy donors. Furthermore to 
evaluate their value as potential drug delivery system the 
cellular uptake has been looked into. The experimental 
setup to investigate the given task consisted of various 
microscopy techniques and different quantitative assays.
Methods
Two dendritic core–shell glycoarchitectures (Fig.  1) 
with different molecular weights of the poly(ethylene 
imine) (PEI) core (25,000 g/mol, defined as PEI-25k-Mal-
B and 5000  g/mol, defined as PEI-5k-Mal-B) have been 
investigated. The dendritic core–shell particles were 
synthesized by reductive amination of PEI in the pres-
ence of minor maltose. The molar ratio between amino 
groups of PEI and maltose is 1–0.5. Further details of 
the synthetic approach can be taken from previously 
described approach by Appelhans et  al. [26]. Both PEI 
were obtained from commercially available source [Lup-
asol G100 for PEI-5k-Mal-B and Lupasol WF for PEI-
25k-Mal-B by BASF SE (Ludwigshafen, Germany)]. The 
used dendritic core–shell glycoarchitectures (Fig.  1) are 
characterized by the molecular structure B where after 
Fig. 1 Synthetic approach of cationic dendritic core–shell glycoarchitectures PEI-5k-Mal-B and PEI-25k-Mal-B [26, 27]. Due to different sizes of 
hyperbranched poly(ethylene imine) cores final dendritic core–shell glycoarchitectures provide different hydrodynamic radii (Rh) [26, 27]
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the reductive amination of PEI the previous peripheral 
or primary amino groups are converted into preferen-
tial secondary amino groups possessing one chemically 
attached maltose unit besides minor tertiary amino 
groups bearing two chemically attached maltose units 
(Fig. 1) [26]. Both PEI-Mal-B macromolecules possess a 
lower cationic surface charge or charge density than their 
parental PEI [26, 27, 33, 40]. Therefore, dendritic core–
shell glycoarchitectures [40] can be considered as weakly 
cationic and spherical polyelectrolyte [26] macromol-
ecules with size dimensions of about 4 nm for the smaller 
nanoparticle PEI-5k-Mal-B (Fig.  1) and of about 14  nm 
for the larger nanoparticle PEI-25k-Mal-B (Fig. 1).
Further details of the charge density are presented in 
the Additional file  1. To emphasize that glycoarchitec-
ture B based on PEI-5k and PEI-25k core molecules is 
a weakly cationic polyelectrolyte, a comparison of the 
established glycoarchitectures A–C [26] is presented 
as pH dependent measurements. One can recognize in 
both cases that the charge density, determined by poly-
electrolyte titration experiments that glycoarchitecture B 
(Fig. 1) has lower cationic charge as found for glycoarchi-
tecture C (possessing lower degree of attached maltose) 
[26] starting from isoelectrical point to lower pH values 
(Additional file 1: Figures S2, S3). The molecular weight 
of both glycoarchitectures were determined as described 
in a previous paper [26]: PEI-5k-Mal-B of about 18,000 g/
mol and PEI-25k-Mal-B of about 38,100 g/mol.
Experimental description for carrying out DLS and 
polyelectrolyte titration experiments are presented in the 
Additional file 1.
Mesenchymal stem cell cultures and osteogenic 
differentiation
Primary rdMSCs, labeled CC1, CC2, CC3 and CC4, have 
been harvested from reaming debris collected during 
trauma surgery at the university hospital Giessen. The 
exact procedure for obtaining vital rdMSC from ream-
ing debris has been described by Wenisch et al. [39] and 
Trinkaus et al. [38]. In brief the harvested reaming debris 
has been incubated at 37 °C and under 5 % CO2 in Petri-
dishes, with cell culture medium (Medium A) consist-
ing of F12k (Gibco, Life Technologies, Carlsbad, USA) 
blended with 20 % fetal calf serum (PanSera ES, Pan Bio-
tech, Aidenbach, Germany) and 1  % penicillin/strepto-
mycin. After the rdMSCs grew out of the reaming debris 
they were harvested using 0.05  % Trypsin (Gibco, Life 
Technologies, Carlsbad, USA) and stored at liquid nitro-
gen temperature. Prior to the experiments the cells have 
been removed from their storage at liquid nitrogen tem-
perature and were gently unfreezed. After thawing they 
were immediately transferred into cell culture bottles 
containing Medium A. Before seeded into 24 well plates 
for the experiments, the used rdMSC were passaged 
at least 2 times, not exceeding 3 times. The cell culture 
medium has been changed every fifth day. All experi-
ments have been conducted in doubles and for all experi-
ments 10,000 cells per cm2 have been seeded out either 
in 24-well plates (functional-assays) or in chamber slides 
(transmission electron microscopy and fluorescence 
microscopy). For our experiments four rdMSC lines have 
been used, all from healthy male donors, between 33 and 
65 years.
To induce osteogenic differentiation in some of our 
experiments, Medium B, prepared as described by 
Trinkaus et  al. [41], composed of Dulbeccos modi-
fied Eagles medium (Gibco, Life Technologies, Carls-
bad, USA) low glucose, 0.05  mM ascorbic acid, 
0.1  μM Dexamethasone, 10  % fetal calf serum, 10  mM 
β-glycerolphosphate and 1 % penicillin/streptomycin was 
added to the cells. The medium has been changed at least 
every fifth day.
Determination of toxicity
To investigate dendritic core–shell glycoarchitectures´ 
toxic effects on rdMSC, 10,000 cells per cm2 have been 
seeded out in 24-well plates (Falcon Multiwell, Becton–
Dickinson, Franklin Lakes, USA). For 1  day unmodified 
Medium A has been applied. On the second day the 
medium was replaced with Medium A containing each 
nanoparticle at a selected time using concentrations of 1 
and 0.05 mg/ml. For each run the medium has been har-
vested after 24 and 72  h, respectively, and immediately 
used to conduct the Cytotox 96® Non-Radioactive Cyto-
toxicity Assay (Promega GmbH, Mannheim, Germany) 
which measures the concentration of lactat dehydroge-
nase (LDH). The remaining cells, after washing 2 times 
in a 10 % phosphate buffered saline (PBS) solution, have 
been frozen at −80  °C. After 24 h the cells were unfro-
zen and 1  ml of 1  % Triton-X lysis buffer per well was 
added. After centrifuging of the lysates, 50  µl of each 
supernatant was treated according to the assay protocol 
of the Cytotox 96® Assay. The total absorbance measured 
at 490  nm is proportional to the LDH concentration in 
the samples. To determine the cytotoxicity the measured 
LDH content in the medium was divided by total LDH 
content, determined by adding LDHmedium + LDHcell. 
All results were measured in triplicate. Quotients of >0.1 
are considered to hint on toxic effects.
Quantification of cell proliferation
The influence on cell proliferation after treatment with 
nanoparticles has been analyzed by again seeding out 
10,000 cells/cm2 in 24 well plates. After 1 day the unmod-
ified medium A was replaced with medium A contain-
ing nanoparticle concentrations of either 1  mg/ml or 
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0.05  mg/ml of PEI-25k-Mal-B or PEI-5k-Mal-B. Three 
different endpoints, 7, 21 and 28 days, were investigated. 
After washing the cells in a 10 % PBS solution, 250 μl of 
1 % Triton X was added. The lysates were centrifuged and 
3 ×  10 μl of each supernatant transferred to three dif-
ferent wells of a 96-well plate. We used the DC-Protein-
Assay (Bio-Rad Laboratories, Hercules, USA) to quantify 
cell numbers. The prepared 96-well plates were treated 
according to the assay protocol. 25 ml of reagent A and 
200  ml of reagent B were added. After 15  min of incu-
bation at room temperature the absorbance at 750  nm 
has been recorded. For each used rdMSC the assay has 
been calibrated by seeding out 10,000, 20,000, 40,000 and 
80,000 cells per Well, performing the DC protein assay, 
subsequently followed by performing a linear regression.
Alkaline phosphatase assay and von‑Kossa‑staining: 
influence of nanoparticles on osteogenic differentiation
The alkaline phosphatase is the leading enzyme of the 
bone metabolism. Its concentration in the cells hints on 
the differentiation behavior of osteogenic cell cultures. 
10,000 cells per cm2 have been seeded out in 24 well 
plates. To induce osteogenic differentiation medium B 
(described above) has been used. Additionally to the 
unmodified Medium B, we assembled medium B con-
taining nanoparticle concentrations of 1, 20 and 50 μg/
ml of PEI-25k-Mal-B or PEI-5k-Mal-B. Every fifth day, 
the medium has been changed. Each modification has 
been tested in doubles for 7, 21 and 28 days. After each 
incubation time the medium has been collected and the 
cells have been washed in 10 % PBS solution. Afterwards, 
250 ml 1 % Triton X lysis buffer has been added and the 
lysates have been centrifuged. According to the test pro-
tocol of the used SensoLyte pnPP ALP Assay (AnaSpec, 
Fremont, USA) 3  ×  10  μl supernatant of each sample 
were added to separate wells of a 96-well plate. After 
addition of the assay buffer and incubation for 45 min at 
37 °C the absorbance at 405 nm has been recorded. The 
absolute amount of ALP has been referenced on the cell 
number obtained by conducting the DC-Protein-Assay.
In addition, to prove synthesis of mineralized matrix, 
von-Kossa stained samples with osteogenic differenti-
ated cells have been manufactured [42]. The von Kossa 
stained samples have been semi-automatically histomor-
phometrically evaluated using ImageJ software [43, 44]. 
For each sample 5 sections, each 1.1 mm × 1.5 mm, have 
been evaluated. The images have been converted to black 
and white, the threshold was set and the mineralized area 
has been measured. The mineralized area of each MSC 
sample has been normalized to the respective non nano-
particle treated reference sample.
Light microscopy
In addition all samples have been checked multiple times, 
using a 090-135.002 light microscope (Leica GmbH, Wet-
zlar, Germany) equipped with a Nikon Ds-Fi1 camera 
(Nikon, Duesseldorf, Germany).
Fluorescence microscopy (CLSM)
In addition to the unmarked nanoparticles, Rhodamine 
B labeled PEI-25k-Mal-B and PEI-5k-Mal-B were used 
to proof cellular uptake of the particles. Intracellular fea-
tures like DNA or actin filaments have been stained by 
4′,6-diamidino-2-phenylindol (DAPI, Carl Roth GmbH, 
Karlsruhe, Germany) for the DNA or phalloidin coupled 
TRITS dye (Sigma-Aldrich, St. Louis, USA) for the actin 
filaments. 10,000 Cells per cm2 were seeded into chamber 
slides. After 1 day treatment with Medium A + nanopar-
ticles (1 mg/ml) the cells were washed and stained accord-
ing to the protocols. For imagining a TCS SPS (Leica 
GmbH, Wetzlar, Germany) microscope has been used, 
excitation and detection wavelengths have been chosen 
as follows: DAPI: excitation 405  nm, detection 460  nm, 
phalloidin-TRITS: excitation 561  nm, detection 577  nm, 
Rh-PEI-Mal-B: excitation 405–498 nm, detection 520 nm.
Transmission electron microscopy (TEM)
Cells have been seeded out in chamber slides and were 
incubated for 60  min and 24  h with a concentration of 
1 mg/ml of each used nanoparticle. At the endpoints the 
cells have been washed with 0.1 M PBS buffer and fixed 
with yellow-fix mixture (2 % paraformaldehyde, 2 % glu-
taraldehyde, 0.02  % picric acid mixed with 0.1  M phos-
phate buffer). After this step fixation in 1  % osmium 
tetroxide in 0.1  M sodium cacodylate buffer took place. 
Dehydration steps, involving washing in rising concen-
trations of alcohol, followed consecutively. The final steps 
of sample preparation involved embedding in EPON 
resin, ultra-thin-cutting (80–100 nm), staining with ura-
nyl acetate and lead citrate and investigation in a LEO912 
(Carl Zeiss AG, Oberkochen, Germany) transmission 
electron microscope.
Statistics
Statistical calculations were done using SPSS V21 (IBM, 
Armonk, USA). For each endpoint either Kruskal–Wal-
lis calculations or, if Gaussian distribution was existent, 
ANOVA with Tukey Post-Hoc tests were calculated. The 
level of significance was set to p  ≤  0.05 and the confi-
dence interval to 95 %. The boxplots show the standard 
error (SE) as the width of the box, the whiskers cover the 
whole range of measured values. The bar displays the 
median while the diamond marks the intersection.
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Results
Toxicity of nanoparticles
Possible toxic effects of the used materials were investi-
gated for both nanoparticles (PEI-25k-Mal-B and PEI-
5k-Mal-B) in different runs with two incubation times 
(24 and 72  h) and two nanoparticle-concentrations (1 
and 0.05 mg/ml). For every separate condition cells have 
been seeded out in doubles. The observed toxic effects of 
the nanoparticles seem to be on the one hand depend-
ent on the used concentrations and on the other hand on 
the molecular weight of the PEI core. In addition a strong 
donor-dependency for adverse effects of both nanoparti-
cles from the used cell culture can be observed (Fig. 2). 
However generally the smaller PEI core for PEI-5k-Mal-
B induces significant lower toxic effects for all incuba-
tion times, concentrations and rdMSC. While for both 
endpoints the toxicity of the higher concentration of 
PEI-25k-Mal-B compared to the untreated reference is 
significant (p = 0.006 for both) (Fig. 3).
Influence on proliferation
Long term investigations with time scales of 7, 21 
and 28  days were conducted. Concentrations of 1 and 
0.05  mg/ml for both nanoparticles have been investi-
gated. The DC-protein-assay was used to quantify total 
cell numbers. The total cell numbers for all four used 
rdMSC-lines combined have been evaluated and are 
displayed in Fig.  4. The long term experiments yield in 
reduced cell numbers when adding nanoparticles, statis-
tically significant for high nanoparticle concentrations of 
both particles and incubation times of 21 and 28 days. In 
the case of PEI-25k-Mal-B a 28  days incubation period 
with the lower nanoparticle concentration also resulted 
in significantly reduced cell numbers. For 7 days the sta-
tistical calculations are not significant but exhibit a cer-
tain trend towards reduced cell numbers for experiments 
with nanoparticles as well.
Osteogenic differentiation
The influence of the nanoparticles on the osteogenic dif-
ferentiation of rdMSC has been investigated by measur-
ing the ALP content of the cells after 7, 21 and 28 days 
as endpoints (Fig. 5b). In consideration of the results of 
the proliferation tests (Fig. 4) decreasing concentrations 
of dendritic core–shell glycoarchitectures (0.05  mg/
ml =  50, 20 and 1 μg/ml) have been selected. As dem-
onstrated in Fig.  5b, the particles, no matter at what 
concentration, induce no change of the measured nor-
malized ALP concentration while the proliferation of 
osteogenic differentiated cells is reduced (Fig.  5a). The 
latter one is comparable to the results obtained from 
the rdMSC-experiments (Fig.  4). In addition von-Kossa 
Fig. 2 Mean cell number after 21 days (black diamonds) and cytotoxicity for 24 h (squares) and 72 h (circles) for each cell culture incubated with 
1 mg/ml PEI-25k-Mal-B. Fast proliferating rdMSC exhibit a pronounced toxic response when treated with nanoparticles
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Fig. 3 Cytotoxicity of plain nanoparticles for two different endpoints and with two concentrations of each nanoparticle, determined by LDH assay. 
For PEI-25k-Mal-B is toxic at its higher concentration, while PEI-5k-Mal-B shows no significant toxic response. The width of the boxes is the SEM while 
the diamonds represent the intersection (**p ≤ 0.01)
Fig. 4 Total cell count after 7, 21 and 28 days, with different concentrations and types of nanoparticles. The horizontal black line for each endpoint 
marks the mean of the reference samples. Differences in cell count are significant after 21 days for 1 mg/ml of each nanoparticle, after 28 days for 
PEI-25k-Mal-B both tested concentrations result in reduced cell numbers (**p ≤ 0.01, *p ≤ 0.05)
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Fig. 5 a Total cell count of osteogenic differentiated cells determined by DC-protein-measurements. After 28 days a significant reduction in cell 
count is observed for all concentrations of PEI-25k-Mal-B and for the higher and the intermediate concentration of PEI-5k-Mal-B (***p < 0.001, 
**p < 0.01). b Normalized ALP content per cell of rdMSC differentiated to osteoblasts and incubated with different concentrations of both nanopar-
ticles. The measured total ALP concentration has been divided by the cell count. As reference for normalization the respective control samples for 
each endpoint have been used. No influence of nanoparticles on the ALP concentration per cell has been detected
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stained samples of osteogenic differentiated rdMSC, with 
and without nanoparticles, have been prepared. Figure 6 
shows large structures of mineralized matrix, deep black 
in the image, which hint on excessive production of 
mineralized matrix and thus on a successful osteogenic 
differentiation for all investigated conditions, weather 
incubated with or without nanoparticles. The histomor-
phometric evaluation of the von-Kossa stained samples 
exhibited no statistically significant deviations from 
the reference samples for all investigated conditions. 
However, while not significant, for the larger particle 
PEI-25k-Mal-B possibly a trend towards higher miner-
alization can be found. For all conditions the addition of 
nanoparticles did not lead to reduced osteogenesis. 
Cellular uptake (fluorescence microscopy)
To proof the cellular uptake of PEI-5k-Mal-B and PEI-
25k-Mal-B by CLSM, both were labeled by Rhodamine 
B (Rh-PEI-5k-Mal-B or Rh-PEI-25k-Mal-B, green) and 
administrated to rdMSC for 24  h with concentrations 
of 0.1  mg/ml. The nucleus and the actin filaments were 
stained with either DAPI (blue) or Phalloidin coupled 
TRITS (red). The reference (Fig.  7a) shows no signs 
of nanoparticles. As shown in Fig.  7b, sample has been 
treated with Rh-PEI-5k-Mal-B where the nanoparticles 
feature a peri-nuclear distribution. For samples incu-
bated with Rh-PEI-25k-Mal-B (Fig.  7c), again a peri-
nuclear particle distribution can be found, in this case the 
nucleus has not been stained (Fig. 7c).
Cell morphology
The development of cell morphology of rdMSC (Fig.  8) 
was investigated by light microscopy when administrating 
nanoparticles PEI-25k-Mal-B and PEI-5k-Mal-B to cells 
for 72  h. In particular cell cultures treated with larger 
PEI-25k-Mal-B in both concentrations exhibit signs of 
cellular damage like for example cellular debris, floating 
free in the medium. Compared to the reference samples 
incubated in unmodified Medium A, even this short time 
exposure seems to reduce the cell count of nanoparticles-
incubated rdMSC too.
Additionally, light microscopy images obtained from 
long-term trials after 21  days are shown in Fig.  9. The 
cells of the untreated reference rdMSC are vital and 
confluent cells. No signs of damage, reduced viability or 
distorted morphology can be found. In contrast to this 
reduced cell counts are observable for both nanoparti-
cles, while for rdMSC treated with PEI-25k-Mal-B signs 
of cellular damage and death, as for example irregular 
nuclei, distorted cell shapes or free floating cell debris, 
can be detected. PEI-5k-Mal-B, in both concentrations, 
induces far less damage and cell debris.
Moreover, morphologic features of cells with osteo-
genic differentiation are also displayed as light micros-
copy images in Fig. 10. Blocks of mineralized matrix can 
be seen in all light microscopy images, especially in the 
von-Kossa stained ones (Fig.  6). Due to the high min-
eralization it is difficult to distinguish cells or parts of 
them. However again the rdMSC samples treated with 
the intermediate (20  µg/ml) and high (50  µg/ml) PEI-
25k-Mal-B concentration exhibit free floating cell debris 
(black dots and circular structures) that hint on toxic 
effects induced by the nanoparticles.
On smaller scales, a deeper insight into the cell mor-
phology in the presence of nanoparticles can be gained by 
transmission electron microscopy (TEM). As incubation 
Fig. 6 Light microscopy images of von-Kossa stained osteogenic samples, incubated with or without addition of nanoparticles. The deep black 
structures represent mineralized matrix
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times 60  min and 24  h have been selected. The shorter 
one to research the uptake and the longer one to investi-
gate possible early cytotoxic effects. All experiments have 
been carried out using nanoparticle concentrations of 
1 mg/ml.
An untreated reference cell can be seen in Fig.  11a. 
No extracellular particles are present, their intracellu-
lar structures are intact. No sign of cellular damage can 
be observed. In contrast, PEI-25k-Mal-B treated cells, 
incubated for 60 min, feature small nanometer-sized par-
ticles, attached to the cell membrane surface (hints by 
arrows in Fig. 11b). Additionally to this, one can impres-
sively recognize the toxic effects of PEI-25k-Mal-B on 
rdMSC viability after 24  h. Mitochondrial damage (see 
Fig.  11c) is exclusively available for PEI-25k-Mal-B, the 
inner structure of the mitochondria is distorted and the 
mitochondrial membrane is beginning to disintegrate. 
Moreover, vesicular structures in the area of rdMSC 
Fig. 7 CLSM images of cell cultures treated with rhodamin B marked nanoparticles (green). The nucleus has been DAPI dyed (blue), the actin fila-
ments were stained with phalloidin coupled TRITS (red). a Displays untreated reference, only the nucleus and the actin-filaments can be observed. 
b Rhodamin B labeled Rh-PEI-5k-Mal-B nanoparticles, surrounding the nucleus. c The rhodamin-marked nanoparticles Rh-PEI-25k-Mal-B feature a 
perinuclear distribution, in this sample the nucleus has not been stained
Fig. 8 Light microscopy images, taken for endpoints of 72 h. rdMSCs treated with nanoparticles and the reference. For samples treated with nano-
particles cells going into apoptosis (for PEI-25k-Mal-B) or reduced cell numbers (both nanoparticles) can be found
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Reference PEI-25k-Mal-B 50µg/ml PEI-25k-Mal-B 1mg/ml
PEI-5k-Mal-B 50µg/ml PEI-5k-Mal-B 1mg/ml
400 µm 400 µm
400 µm
400 µm
400 µm
200µm
PEI-5k-MalB 50µg/ml 21d
200µm
PEI-5k-MalB 1mg/ml 21d
400µm
200µm
PEI-25k-MalB 1mg/ml 21d
200µm
PEI-25k-MalB 50µg/ml 21d
a
b
Fig. 9 a Light microscopy images for long-term trials with endpoint 21 days. Compared to the reference especially the rdMSC treated with PEI-
25k-MAL-B exhibit damaged cells and free floating cell debris, while rdMSC incubated with PEI-5k-Mal-B show less signs of damage. b Light micros-
copy images with higher magnification of cells treated with nanoparticles for 21 days. Especially PEI-25k-Mal-B results in large amounts of cellular 
debris (white structures) and damaged cells (arrows), while PEI-5k-Mal-B doesn’t harm cells in that way
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membrane can be also visualized when applying smaller 
nanoparticles PEI-5k-Mal-B. This structural detail during 
the cellular uptake process of nanoparticles is presented 
in Fig. 11d.
Discussion
Dendritic glycopolymers, and in particular oligosaccha-
ride-modified PEI nanoparticles, provide a large variety 
of desired features for applications in biomedicine [45]. 
However one has to weigh the pros and cons of their 
usage and carefully investigate and analyze their positive 
and negative influences on cells and organism. Prior to 
in  vivo applications of these nanoparticles an extensive 
and diligent in  vitro testing is necessary for acquiring 
their biological properties against rdMSC and in differen-
tiation process of rdMSC to osteoblasts.
To gain maximal results from the experimental set-
ups it is crucial to conduct on the one hand experiments 
with a variety of cells from different donors and on the 
other hand to expand the experimental time-scales up to 
28  days. To the best of our knowledge, such long-term 
in  vitro experiments have not been undertaken so far, 
neither with plain rdMSC nor with osteoblasts. In detail, 
one of our most important tasks was to determine any 
donor dependent variability in the impact of the used 
nanoparticles on the different rdMSC lines. For primary 
rdMSC it has been reported that there is a large donor-
to-donor variance for example for the proliferation of 
cells [46] or the influence of growth inhibitors on cells 
[47]. Our experiments yielded that for as well untreated 
cells as ones incubated with nanoparticles the speed of 
proliferation shows a large donor-dependent variability. 
A very interesting finding here is that there is a connec-
tion between the speed of proliferation and the observed 
toxicity. The fast proliferating cell cultures (CC1 and 
CC4) reveal a considerably higher toxic response com-
pared to the low-proliferating CC2 and the intermediate 
one CC3 (Fig. 2).
While cells incubated with PEI-5k-Mal-B showed no 
microscopic signs of toxicity, in most the cases the mito-
chondrial system of cells treated with PEI-25k-Mal-B 
was negatively affected by these larger glycoarchitec-
tures (Fig.  11c). One possible origin of toxicity from 
core–shell glycoarchitecture nanoparticles is the genera-
tion of reactive oxygen species (ROS) [48] that interfere 
with the mitochondrial system [49] and drive the cell 
into apoptosis. Comparable results from literature up to 
now are mainly available for different dendritic struc-
tures. First Kuo et al. [23] found out that cationic paren-
tal poly(propylene imine) (PPI) dendrimers influence the 
generation of ROS in human macrophages. Addition-
ally they proposed that the equilibrium between ROS 
generation and detoxification, which is essentially for 
macrophages, is disturbed and the generation of ROS is 
increased in such cells. Janaszewska et  al. [24] investi-
gated the influence of unmodified PPI, maltotriose modi-
fied PPI and poly(amidoamine) (PAMAM) dendrimers 
on human and hamster ovarian carcinoma cells. Again 
the generation of ROS has been identified as one main 
source of toxicity. In this context the cationic open shell 
PPI glycodendrimers also provides toxicity behavior at 
higher concentration. Calarco et  al. [22] reported about 
reactive oxygen species (ROS) that play a role in PEI 
induced cell damage while the surface-modified PEI nan-
oparticles also outlines reduced genotoxicity. Together 
with the reports from literature, our TEM images 
(Fig. 11c) suggest that for administrating PEI-25k-Mal-B 
mitochondrial damage, caused by the generation of ROS, 
Fig. 10 Light microscopy images of osteogenic differentiated cells for the endpoint 28 days. From the images no influence on differentiation of 
cells from nanoparticles can be distinguished, cell debris can be found for PEI-25k-MAL-B treated samples
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drives the cell into apoptosis. Additional to the inter-
species dependent variability in the toxic response of the 
cells [24], we found a significant donor-to-donor variable 
toxicity for our rdMSC. This implies a new key aspect 
which has to be considered in future in vitro studies with 
oligosaccharide-modified PEI nanoparticles, but may be 
also for other types of nanosized carrier systems.
The second important task to investigate was the long 
term influence of the used nanoparticles on a time scale 
up to 28  days. Most experiments preferentially inves-
tigated incubation times of ≤72  h [22, 25, 27, 50, 51] 
to describe undesired effects such as toxic effects and 
reduced proliferation already to be detectable after 24 h, 
but also at longer incubation times of 48 and 72 h. How-
ever none of the experiments extended their incubation 
times up to a point when a steady state of negative effects 
has been reached. In consequence we extended the end-
points of our proliferation and differentiation experi-
ments up to 28 days. Early toxic effects are preferentially 
observable on a time scale between 24 and 72 h and can 
be quantified by the LDH release and optical micros-
copy. In particular for the larger particle PEI-25k-Mal-
B, we found that undesired toxic effects began to occur 
after 24–72  h incubation time. This is in good agree-
ment with other authors [22, 25, 27, 50, 51]. However, 
the long-term experiments after 21 and 28  days visu-
alized by light microscopy gave a deeper insight on the 
biological action of both core–shell glycoarchitectures 
on rdMSC (Fig.  9). In line with this countable (toxic) 
effects of both core–shell glycoarchitectures can be 
Fig. 11 TEM images of a reference without nanoparticles, b PEI-25k-MAL-B treated cells, small structures (marked with arrows) sticking on the cell 
membrane can be seen c PEI-25k-MAL-B treated cells, endpoint 24 h, the arrows mark signs of mitochondrial destruction d PEI-5k-MAL-B treated 
samples, vesicular uptake of nanoparticles can be seen
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quantified by the determination of reduced cell numbers 
after 21 and 28 days by using DC protein assay (Fig. 4). 
For both nanoparticles it gives a marginal or slight differ-
ence in the cell numbers after 21 and 28 days. The light 
microscopy images show lots of cellular debris float-
ing free around the cells. Therefore, we assume that the 
reduced cell number in our long term experiments is also 
caused by the generation of ROS followed up by apopto-
sis. Of course the presence of other negative influences 
like for example direct interference with nucleic acids, 
denaturation of proteins or inflammatoric response can-
not be completely excluded at the moment. Thus, the 
observed toxic effects of core–shell glycoarchitectures 
were mainly dependent on the molecular weight of the 
particle and the concentrations used. Both nanoparti-
cles have the same degree on maltose shell decoration. It 
mainly implies that this parameter has a lower influence 
on the biological action of both nanoparticles. In princi-
ple both core–shell glycoarchitectures are not completely 
comparable with other PEI structures, but it gives a good 
agreement with the results reported by Fischer et al. [18]. 
They also describe a molecular-weight-dependent behav-
ior for their naked, unmodified PEI molecules. In our 
case negative influences on cell count and proliferation 
of the smaller particle PEI-5k-Mal-B are minimal, if not 
completely absent, while the negative influences are even 
more pronounced for the larger particle PEI-25k-Mal-
B. Similar results obtained from in  vivo experiments in 
mice conducted by Gutsch et al. [33] who described that 
PEI-5k-Mal-B features a superior biocompatibility due to 
their reduced surface charge, while unmodified PEI nan-
oparticle with molecular weight of 5000  g/mol (PEI-5k) 
outlines enhanced toxic effects. In line with this denser 
oligosaccharide shell on PEI-5k also provides enhanced 
biocompatibility [33]. In addition to this Höbel et  al. 
[27] used SKOV3 cells for testing the biocompatibility 
of oligosaccharide-modified PEI-5k and only found toxic 
effects almost exclusively for naked PEI-5k molecules. 
Overall the core–shell glycoarchitecture PEI-5k-Mal-
B5k was successfully tested in various in vitro and in vivo 
experiments showing desired biocompatibility and car-
rier properties for various nucleic acid derivates [26, 
27, 33]. Finally, one can conclude from these long-term 
results (21 and 28  days) that PEI-5k-Mal-B shows more 
promising biological effects/properties in the presence 
of rdMSC than the larger PEI-25k-Mal-B in our study. 
Moreover, in the course of short-term experiments (≤3 
or 7  days), again PEI-5k-Mal-B is the most favorite of 
tested core–shell glycoarchitectures where the molecu-
lar weight of PEI core plays the most important key rule 
in the biological action of nanoparticles used here in our 
study.
Fig. 12 Statistical, histomorphometric evaluation of the von-Kossa stained samples. The area of mineralized matrix is referenced to the respective 
reference sample for each condition. (For PEI-25k-Mal-B p = 0.163, for PEI-5k-Mal-B p = 0.511)
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Despite the long-term effects of cationic core–shell gly-
coarchitectures on cell viability and proliferation, the dif-
ferentiation of rdMSC to osteoblasts is not influenced by 
the nanoparticles (Fig. 5). In opposite to (slightly) lower 
cell number in the presence of nanoparticles (Fig.  5a), 
the ALP content of the cells (Fig.  5b) and the produc-
tion of mineralized matrix (Figs. 6, 12) in the absence and 
presence of nanoparticles do not differ statistically sig-
nificant. Further studies if (oligo-)maltose-modified-PEI 
nanoparticles with higher molecular weights influence 
osteogenesis in a positive way, as it might be suggested 
by the histomorphometric evaluation of the von-Kossa 
stained samples, might have a chance of success if we 
first succeed in further improvement of biocompatibil-
ity. Certainly none of the used (oligo-)maltose-modified-
PEI nanoparticles in our case influences the capability of 
osteogenic differentiation in a negative way. This behav-
ior has been reported for other nanoparticle-systems, for 
example, using low concentrations of Ag nanoparticles 
[52]. Again, only the further study by light microscopy 
will give a clear key feature of both core–shell glycoarchi-
tectures on differentiated rdMSC (Fig.  10). Only in the 
case of PEI-25k-Mal-B cell morphology is clearly influ-
enced showing the presence of cell debris. This enables us 
to conclude that the cell function after the differentiation 
of rdMSC to osteoblasts, checked by the ALP content, 
is not the deciding experiment (Fig. 5b) to do final con-
clusion on the long-term biological action of both core–
shell glycoarchitectectures. Only the combination of light 
microscopic study (Fig.  10) and determination of DC-
protein measurement (Fig.  5a) and ALP determination 
(Fig. 5b) gives us a deeper view on the biological action 
of both nanoparticles where the smaller PEI-5k-Mal-B is 
the most promising core–shell glycoarchitecture in these 
experiment series. With this in mind, one may postulate 
that the core–shell glycoarchitecture PEI-5k-Mal-B with 
the smaller PEI-5k core can be used as drug delivery sys-
tem for treating bone disease in locally applied therapy.
Conclusion
In summary we have demonstrated that maltose-modified 
poly(ethylene imine) (PEI)nanoparticles with PEI-5k and 
PEI-25k core feature a good uptake in primary mesenchy-
mal stem cells. They do not negatively interfere with the 
differentiation capabilities of those, but induce different 
toxic and proliferation-inhibiting effects. The later ones 
are mainly tailored by the molecular weight of PEI core 
and the maltose shell modification of each PEI core. For 
the larger core–shell glycoarchitectures PEI-25k-Mal-B 
effects on the mitochondrial system is clearly visible by 
TEM images. Due to large differences in the interaction 
between cells and nanoparticles donor-to-donor variabil-
ity of the used rdMSC has to be taken into account.
The most important breakthrough of this study was 
to evaluate the influence of incubation time (3, 21 and 
28 days) of nanoparticles on the proliferation of rdMSC. 
To detect toxic effects of administered nanoparticles 
it seems crucial to use at least endpoints of 3 days con-
sidered as short-term experiments. Here, only first side 
effects on cell proliferation can be determined. Negative 
effects on the cell proliferation can be reliably detected 
after 21  days, considered as long-term experiments. 
Finally the particle with the lower molecular weight of 
the PEI-5k core, PEI-5k-Mal-B, features superior bio-
compatibility compared to those of PEI-25k-Mal-B. For 
PEI-5k-Mal-B lower early toxic effects and only slight 
effects on cellular proliferation are detectable in short- 
and long-term experiments. The cellular integrity stayed 
intact in rdMSC treated with this particle. This makes 
PEI-5k-Mal-B a suitable candidate as drug delivery vehi-
cle for future in vitro and in vivo studies.
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